Clinically Meaningful Responses to Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications in the Randomized, Placebo-Controlled FOCUS Study

被引：0
|
作者：
Spierings, Egilius L. H. [1 ]
Ning, Xiaoping [2 ]
Galic, Maja [3 ]
Cohen, Joshua M. [2 ]
Yang, Ronghua [2 ]
机构：
[1] Medvadis Res Corp, Watertown, MA USA
[2] Teva Pharmaceut Ind, Frazer, PA USA
[3] Teva Pharmaceut, Amsterdam, Netherlands
来源：
ANNALS OF NEUROLOGY | 2019年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
M195
引用
收藏
页码：S168 / S168
页数：1
相关论文
共 50 条
  • [41] Very early onset of action of fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the international, multicentre, randomised, placebo-controlled FOCUS study
    Brandes, Jan
    Ramirez-Campos, Verena
    Yang, Ronghua
    Cohen, Joshua M.
    Galic, Maja
    Ning, Xiaoping
    Treppendahl, Christina
    CEPHALALGIA, 2019, 39 : 11 - 12
  • [42] Early onset of response to fremanezumab in migraine patients with moderate to severe depression and documented inadequate response to 2-4 classes of migraine preventive treatments: subgroup analysis of the randomised, placebo-controlled FOCUS study
    Blumenfeld, Andrew
    Yang, Ronghua
    Cohen, Joshua M.
    Ramirez-Campos, Verena
    Rosich, Patricia Pozo
    CEPHALALGIA, 2019, 39 : 209 - 210
  • [43] Efficacy of fremanezumab in patients with migraine and documented inadequate response to 2, 3, or 4 classes of migraine preventive treatments: results of the international, multicenter, randomised, placebo-controlled FOCUS study
    Pazdera, Ladislav
    Ning, Xiaoping
    Galic, Maja
    Cohen, Joshua M.
    Yang, Ronghua
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (SUPPL 1):
  • [44] Impact of fremanezumab on any acute headache medication use in migraine patients with medication overuse and documented inadequate response to 2-4 migraine preventive medications in the multicentre, randomised, placebo-controlled FOCUS study
    Newman, Lawrence
    Cohen, Joshua M.
    Ramirez-Campos, Verena
    Janka, Lindsay
    Diener, Hans-Christoph
    CEPHALALGIA, 2019, 39 : 238 - 238
  • [45] Reversion from chronic to episodic migraine in patients with documented inadequate response to 2-4 classes of migraine preventive treatments: results of the randomised, placebo-controlled FOCUS study
    Ailani, Jessica
    Ramirez-Campos, Verena
    Cohen, Joshua M.
    Yang, Ronghua
    Galic, Maja
    Ning, Xiaoping
    Singh, Rashmi Halker
    CEPHALALGIA, 2019, 39 : 222 - 222
  • [46] Clinically Meaningful Responses to Fremanezumab in Patients With Migraine and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes in the Open-label Period of the International, Multicenter Phase 3b FOCUS Study
    Gladstone, Jonathan
    Ning, Xiaoping
    Cohen, Joshua M.
    Ramirez-Campos, Verena
    Yang, Ronghua
    Spierings, Egilius L. H.
    NEUROLOGY, 2020, 94 (15)
  • [47] Efficacy of fremanezumab in patients with migraine and documented inadequate response to valproic acid and 2-3 other classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study
    Pazdera, L.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Yang, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 633 - 633
  • [48] Long-term Efficacy of Fremanezumab in Patients With Chronic or Episodic Migraine and Documented Prior Inadequate Response to 2-4 Classes of Migraine Preventive Medications
    Naegel, S.
    Cohen, J. M.
    Campos, V. Ramirez
    Barash, S.
    Ning, X.
    Kudrow, D.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 170 - 170
  • [49] Long-term Efficacy of Fremanezumab in Patients With Chronic or Episodic Migraine and Documented Prior Inadequate Response to 2-4 Classes of Migraine Preventive Medications
    Nagel, S.
    Cohen, J. M.
    Campos, V. Ramirez
    Barash, S.
    Ning, X.
    Kudrow, D.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 114 - 114
  • [50] Improvement in Headache-related Disability with Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes in the International, Multicenter, Randomized FOCUS Study
    Ashina, M.
    Ferrari, M. D.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Yang, R.
    HEADACHE, 2019, 59 : 111 - 111
12345